Literature DB >> 31090840

Coexistence of segmental vitiligo, scleroderma en coup de sabre and cleft lip on the same hemiface: association with mosaicism?

Heloísa Del Castanhel Ubaldo1, Caio César Silva de Castro1,2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31090840      PMCID： PMC6486066          DOI： 10.1590/abd1806-4841.20198110

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN： 0365-0596            Impact factor:   1.896


× No keyword cloud information.
  5 in total

Review 1.  Segmental Vitiligo.

Authors:  Nanja van Geel; Reinhart Speeckaert
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

2.  Linear scleroderma en coup de sabre including abnormal dental development.

Authors:  M Hørberg; S R Lauesen; J Daugaard-Jensen; I Kjær
Journal:  Eur Arch Paediatr Dent       Date:  2014-10-30

3.  Simultaneous occurrence of linear scleroderma and homolateral segmental vitiligo.

Authors:  C Bonifati; G Impara; A Morrone; A Pietrangeli; M Carducci
Journal:  J Eur Acad Dermatol Venereol       Date:  2006-01       Impact factor: 6.166

4.  Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients.

Authors:  Claire Regazzetti; Florence Joly; Carine Marty; Michel Rivier; Bruno Mehul; Pascale Reiniche; Carine Mounier; Yves Rival; David Piwnica; Marine Cavalié; Bérengère Chignon-Sicard; Robert Ballotti; Johannes Voegel; Thierry Passeron
Journal:  J Invest Dermatol       Date:  2015-08-31       Impact factor: 8.551

5.  Disrupting hedgehog and WNT signaling interactions promotes cleft lip pathogenesis.

Authors:  Hiroshi Kurosaka; Angelo Iulianella; Trevor Williams; Paul A Trainor
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808
  5 in total
  1 in total

Review 1.  Autoimmunity in Segmental Vitiligo.

Authors:  Reinhart Speeckaert; Jo Lambert; Vedrana Bulat; Arno Belpaire; Marijn Speeckaert; Nanja van Geel
Journal:  Front Immunol       Date:  2020-10-27       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.